Blood-based biomarkers used to predict disease activity in crohn's disease and ulcerative colitis

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1132-1140

  Burakoff, Robert ^a   Pabby, Vikas ^b   Onyewadume, Louisa ^a   Odze, Robert ^a   Adackapara, Cheryl ^a   Wang, Wei ^a   Friedman, Sonia ^a   Hamilton, Matthew ^a   Korzenik, Joshua ^a   Levine, Jonathan ^a   Makrauer, Frederick ^a   Cheng, Changming ^c   Smith, Hai Choo ^d   Liew, Choong Chin ^c,d   Chao, Samuel ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Deputy director of Shanghai Institute of Blood Transfusion SBC   (China)

^d GoldenHealthDx   (Canada)

^e Gene News Corporation   (Canada)

Author keywords

biomarker; gene expression; inflammatory bowel disease

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA;

ADULT; ARTICLE; BLOOD; BLOOD ANALYSIS; BLOOD ANALYSIS EQUIPMENT; CLINICAL ARTICLE; COLON BIOPSY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DYSPLASIA; FEMALE; GENE EXPRESSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION; SEROLOGY; TIME; TUBE; ULCERATIVE COLITIS; ADOLESCENT; CASE CONTROL STUDY; COLITIS, ULCERATIVE; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; BIOMARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 84929083225     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000340     Document Type: Article

References (35)

1. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012;41:483-495.
2. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-Analysis. BMJ. 2010;341:c3369.
3. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-460.
4. Rockett JC, Burczynski ME, Fornance AJ, et al. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol. 2004;194:189-199.
5. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006;147:126-132.
6. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010;125: 1177-1186.
7. Yip KT, Das PK, Suria D, et al. A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res. 2010;29:128.
8. Burakoff R, Hande S, Ma J, et al. Differential regulation of peripheral leukocyte genes in patients with active Crohn's disease and Crohn's disease in remission. J Clin Gastroenterol. 2010;44:120-126.
9. Burakoff R, Chao S, Perencevich M, et al. Blood-based biomarkers can differentiate ulcerative colitis from Crohn's disease and noninflammatory diarrhea. Inflamm Bowel Dis. 2011;17:1719-1725.
10. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
11. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8: 357-363.
12. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148: 1293-1307.
13. Schadt EE, Woo S, Hao K. Bayesian method to predict individual SNP genotypes from gene expression data. Nat Genet. 2012;44:603-608.
14. Harrison RL. Introduction to Monte Carlo simulation. AIP Conf Proc. 2010;1204:17-21.
15. Galamb O, Gyorffy B, Sipos F, et al. Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. Dis Markers. 2008;25;1-16.
16. Akazawa A, Sakaida I, Higaki S, et al. Increased expression of tumor necrosis factor-Alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol. 2002;37:345-353.
17. Dieckgraefe BK, Stenson WF, Korzenik JR, et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics. 2000;4:1-11.
18. Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13:807-821.
19. Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748-761.
20. Mesko B, Poliska S, Szegedi A, et al. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics. 2010;3:15.
21. van Lierop PP, Swagemakers SM, de Bie CI, et al. Gene expression analysis of peripheral cells for subclassification of pediatric inflammatory bowel disease in remission. PLoS One. 2013;8:e79549.
22. Zhong Y, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol. 2013;4:333. eCollection 2013.
23. Vladimer GI, Weng D, Paquette SW, et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity. 2012;37:96-107.
24. Chen GY. Role of Nlrp6 and Nlrp12 in the maintenance of intestinal homeostasis. Eur J Immunol. 2014;44:321-327.
25. Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011;106:1272-1280.
26. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-Analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
27. Festen EA, Goyette P, Green T, et al. A meta-Analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet. 2011; 7:e1001283.
28. Kadoshima-Yamaoka K, Murakawa M, Goto M, et al. ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes. Immunol Lett. 2009;122:193-197.
29. Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm. 2014;2014:325129.
30. Correa PA, Molina JF, Pinto LF, et al. TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62:363-365.
31. Singal DP, Ye M, Qiu X, et al. Polymorphisms in the TAP2 gene and their association with rheumatoid arthritis. Clin Exp Rheumatol. 1994;12: 29-33.
32. Kumagai S, Kanagawa S, Morinobu A, et al. Association of a new allele of the TAP2 gene, TAP2 Bky2 (Val577), with susceptibility to Sjogren's syndrome. Arthritis Rheum. 1997;40:1685-1692.
33. Heresbach D, Alizadeh M, Bretagne JF, et al. TAP gene transporter polymorphism in inflammatory bowel diseases. Scand J Gastroenterol. 1997; 32:1022-1027.
34. Bruzzoni-Giovanelli H, Faille A, Linares-Cruz G, et al. SIAH-1 inhibits cell growth by altering the mitotic process. Oncogene. 1999;18:7101-7109.
35. Liu J, Stevens J, Rote CA, et al. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell. 2001;7:927-936.